# Company Registration Number: 09075426 (England and Wales)

Unaudited abridged accounts for the year ended 30 June 2024

Period of accounts

Start date: 01 July 2023

**End date: 30 June 2024** 

# Contents of the Financial Statements for the Period Ended 30 June 2024

**Balance sheet** 

Notes

## **Balance sheet**

## As at 30 June 2024

	Notes	2024	2023
		£	£
Fixed assets			
Intangible assets:	3	5,005,001	5,001
Investments:	4	1,132,030	0
Total fixed assets:	<del>-</del>	6,137,031	5,001
Current assets			
Debtors:		22,039	836
Cash at bank and in hand:		78,680	45,999
Total current assets:	_	100,719	46,835
Creditors: amounts falling due within one year:		(42,214)	(600)
Net current assets (liabilities):	_	58,505	46,235
Total assets less current liabilities:		6,195,536	51,236
Total net assets (liabilities):	_ _	6,195,536	51,236
Capital and reserves			
Called up share capital:		25,692	19,442
Share premium account:		6,669,310	425,560
Profit and loss account:		(499,466)	(393,766)
Shareholders funds:	- -	6,195,536	51,236

The notes form part of these financial statements

#### **Balance sheet statements**

For the year ending 30 June 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

This report was approved by the board of directors on 22 March 2025 and signed on behalf of the board by:

Name: Simon Slatter Status: Director

The notes form part of these financial statements

## Notes to the Financial Statements

for the Period Ended 30 June 2024

## 1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

## **Notes to the Financial Statements**

## for the Period Ended 30 June 2024

# 2. Employees

	2024	2023
Average number of employees during the period	3	0

## **Notes to the Financial Statements**

## for the Period Ended 30 June 2024

# 3. Intangible Assets

	Total
Cost	£
At 01 July 2023	5,001
Additions	5,000,000
At 30 June 2024	5,005,001
Amortisation	
At 01 July 2023	0
Charge for year	0
At 30 June 2024	0
Net book value	
At 30 June 2024	5,005,001
At 30 June 2023	5,001

#### **Notes to the Financial Statements**

#### for the Period Ended 30 June 2024

#### 4. Fixed investments

On 16 April 2024 the Company purchased 100 Ordinary shares of AS 51 each in One Health Ventures Pty (a company incorporated in Australian) representing 100% of that company's issued share capital. All further transfers to One Health Ventures Pty have been by way of equity subscription. It's principal activity is research and development of an Epsilon toxin vaccine for humans. For the period ended 30 June 2024 the company's management accounts showed a loss of As1,887,402.

Group accounts have not been prepared as the Directors consider that they would not be of material benefit to the Members

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.